Šťastný M - Search Results

1

Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with Melanoma.

Krajsová I, Arenberger P, Lakomý R, Kubala E, Březinová I, Poprach A, Šťastný M, Mužík J, Melichar B. Krajsová I, et al. Among authors: stastny m. Anticancer Res. 2015 Nov;35(11):6303-10. Anticancer Res. 2015. PMID: 26504067

2

Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer?

Svaton M, Bratova M, Koubkova L, Fischer O, Melichar B, Hrnciarik M, Dolezal D, Bilek O, Krejci J, Drosslerova M, Dlouha Z, Blazek J, Majkova P, Brozova L, Stastny M. Svaton M, et al. Among authors: stastny m. Anticancer Res. 2022 Apr;42(4):1987-1995. doi: 10.21873/anticanres.15677. Anticancer Res. 2022. PMID: 35347019

3

HPMA-hydrogels result in prolonged delivery of anticancer drugs and are a promising tool for the treatment of sensitive and multidrug resistant leukaemia.

St'astný M, Plocová D, Etrych T, Ulbrich K, Ríhová B. St'astný M, et al. Eur J Cancer. 2002 Mar;38(4):602-8. doi: 10.1016/s0959-8049(01)00421-x. Eur J Cancer. 2002. PMID: 11872356

4

HPMA copolymer-bound doxorubicin targeted to tumor-specific antigen of BCL1 mouse B cell leukemia.

Kovár M, Mrkvan T, Strohalm J, Etrych T, Ulbrich K, Stastný M, Ríhová B. Kovár M, et al. Among authors: stastny m. J Control Release. 2003 Oct 30;92(3):315-30. doi: 10.1016/s0168-3659(03)00340-7. J Control Release. 2003. PMID: 14568412

5

HPMA-hydrogels containing cytostatic drugs. Kinetics of the drug release and in vivo efficacy.

St'astný M, Plocová D, Etrych T, Kovár M, Ulbrich K, Ríhová B. St'astný M, et al. J Control Release. 2002 May 17;81(1-2):101-11. doi: 10.1016/s0168-3659(02)00047-0. J Control Release. 2002. PMID: 11992683

6

Doxorubicin bound to a HPMA copolymer carrier through hydrazone bond is effective also in a cancer cell line with a limited content of lysosomes.

Ríhová B, Etrych T, Pechar M, Jelínková M, Stastný M, Hovorka O, Kovár M, Ulbrich K. Ríhová B, et al. Among authors: stastny m. J Control Release. 2001 Jul 6;74(1-3):225-32. doi: 10.1016/s0168-3659(01)00320-0. J Control Release. 2001. PMID: 11489498

7

Acquired and specific immunological mechanisms co-responsible for efficacy of polymer-bound drugs.

Ríhová B, Strohalm J, Kubácková K, Jelínková M, Hovorka O, Kovár M, Plocová D, Sírová M, St'astný M, Rozprimová L, Ulbrich K. Ríhová B, et al. J Control Release. 2002 Jan 17;78(1-3):97-114. doi: 10.1016/s0168-3659(01)00489-8. J Control Release. 2002. PMID: 11772452

8

Differences in the intracellular fate of free and polymer-bound doxorubicin.

Hovorka O, St'astný M, Etrych T, Subr V, Strohalm J, Ulbrich K, Ríhová B. Hovorka O, et al. J Control Release. 2002 Apr 23;80(1-3):101-17. doi: 10.1016/s0168-3659(02)00016-0. J Control Release. 2002. PMID: 11943391

9

Abnormal differentiation of thymocytes induced by free cyclosporine is avoided when cyclosporine bound to N-(2-hydroxypropyl)methacrylamide copolymer carrier is used.

St'astný M, Ulbrich K, Strohalm J, Rossmann P, Ríhová B. St'astný M, et al. Transplantation. 1997 Jun 27;63(12):1818-27. doi: 10.1097/00007890-199706270-00020. Transplantation. 1997. PMID: 9210511

10

Targeting of human and mouse T-lymphocytes by monoclonal antibody-HPMA copolymer-doxorubicin conjugates directed against different T-cell surface antigens.

Jelínková M, Strohalm J, Plocová D, Subr V, St'astný M, Ulbrich K, Ríhová B. Jelínková M, et al. J Control Release. 1998 Mar 31;52(3):253-70. doi: 10.1016/s0168-3659(97)00210-1. J Control Release. 1998. PMID: 9743446

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

62 results

Search Page

Filters